Temsirolimus is the first-in-class mammalian target of rapamycin (mTOR) inhibitor that was approved for the treatment of patients with advanced poor prognosis renal cell carcinoma (Hudes et al, 2007).
A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Findings of a new study introduce new drug targets to selectively inhibit a key event in tumor cell progression. The study provides further insight into the control of mTORC1 activation, and ...
Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health. The agreement will see PureTech create a subsidiary, resTORbio, to move the assets into a phase 2b trial in diseases linked to ...
It has long been known that the protein TOR – Target of Rapamycin – controls cell growth and is involved in the development of diseases such as cancer and diabetes. Through a collaborative effort ...
Am J Health Syst Pharm. 2010;67(24):2095-2106. The second mTOR complex, mTORC2, contains mTOR, mLST8, and several unique proteins, including rictor (rapamycin-insensitive companion of mTOR). Rapamycin ...
Predictive gene signature for trabectedin efficacy in advanced soft‐tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study. New soft tissue sarcoma (STS) transcriptomic clusters to ...
BOSTON-- (BUSINESS WIRE)--PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced the initiation of a Phase 2b study of its mechanistic target of ...
In a recent study published in Nature Metabolism, researchers conducted clinical studies on murine animals and humans to evaluate the impact of high protein intake on the amino acid-mammalian target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results